{"name":"Gruppo Oncologico del Nord-Ovest","slug":"gruppo-oncologico-del-nord-ovest","ticker":"","exchange":"","domain":"","description":"Gruppo Oncologico del Nord-Ovest is a specialized oncology-focused pharmaceutical company dedicated to the research, development, and commercialization of innovative cancer treatments. The company has a robust pipeline with 15 drugs in various stages of development, including Denosumab and Docetaxel-Cisplatin-5-Fluorouracil, which are in Phase 2 and Phase 3 trials, respectively.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"L-leucovorin","genericName":"L-leucovorin","slug":"l-leucovorin","indication":"Colorectal cancer (in combination with fluorouracil)","status":"phase_3"},{"name":"docetaxel - cisplatin - 5-fluorouracil","genericName":"docetaxel - cisplatin - 5-fluorouracil","slug":"docetaxel-cisplatin-5-fluorouracil","indication":"Metastatic breast cancer","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Leucovorin and 5-FU","genericName":"Leucovorin and 5-FU","slug":"leucovorin-and-5-fu","indication":"Other","status":"marketed"},{"name":"Pembolizumab","genericName":"Pembolizumab","slug":"pembolizumab","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"L-leucovorin","genericName":"L-leucovorin","slug":"l-leucovorin","phase":"phase_3","mechanism":"L-leucovorin is a reduced folate that enhances the cytotoxic activity of fluorouracil by stabilizing the ternary complex between fluorodeoxymonophosphate, thymidylate synthase, and the reduced folate cofactor.","indications":["Colorectal cancer (in combination with fluorouracil)","Metastatic colorectal cancer","Adjuvant treatment of colorectal cancer"],"catalyst":""},{"name":"Leucovorin and 5-FU","genericName":"Leucovorin and 5-FU","slug":"leucovorin-and-5-fu","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Pembolizumab","genericName":"Pembolizumab","slug":"pembolizumab","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"docetaxel - cisplatin - 5-fluorouracil","genericName":"docetaxel - cisplatin - 5-fluorouracil","slug":"docetaxel-cisplatin-5-fluorouracil","phase":"phase_3","mechanism":"Docetaxel inhibits microtubule dynamics, disrupting cell division, while cisplatin induces DNA crosslinks, and 5-fluorouracil inhibits thymidylate synthase.","indications":["Metastatic breast cancer","Non-small cell lung cancer","Ovarian cancer"],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":2,"marketed":1,"phase_2":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}